SLC5A2 and type 2 diabetes mellitus: The seven selected studies, summarized in Table 1, encompass RCTs and one posthoc analysis, all focusing on the cardiovascular and renal outcomes of SGLT2 inhibitors and GLP-1 RAs in patients with type 2 diabetes.